BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
BIVI is expected to report earnings to fall 25.00% to -15 cents per share on August 28
Q2'24
Est.
$-0.15
Q1'24
Est.
$-0.20
Q4'23
Est.
$-0.23
Q3'23
Est.
$-0.29
Q2'23
Est.
$-0.25
The last earnings report on May 10 showed earnings per share of -20 cents, meeting the estimate of -20 cents. With 305.53K shares outstanding, the current market capitalization sits at 20.11M.